Co-transfection of PDGF-B antisense oligonucleotide and tissue-type plasminogen activator gene prevents vascular anastomotic restenosis after coronary bypass
- VernacularTitle:转染PDGF-B反义核酸和tPA基因预防狗冠脉搭桥术吻合口再狭窄
- Author:
Jun JI
;
Lequn JI
;
Yifan ZHANG
;
Wenping LING
- Publication Type:Journal Article
- Keywords:
Coronary restenosis;
Tissue plasminogen activator;
Platelet-derived growth factor
- From:
Chinese Journal of Pathophysiology
2000;0(11):-
- CountryChina
- Language:Chinese
-
Abstract:
AIM: To elucidate the co-transfection of platelet derived growth factor B(PDGF-B) antisense oligonucleotide and tissue-type plasminogen activator gene to prevent vascular anastomotic restenosis after coronary bypass.METHODS: A dog model of vascular anastomotic restenosis after coronary bypass was constructed. A constructed tissue-type plasminogen activator(tPA) gene plasmid and a designed PDGF-B oligonucleotide were used to transfect into the dog cardiomyocytes and anastomotic vascular smooth muscle cells(VSMCs) at the same time of coronary bypass, using a therapeutic ultrasound for the gene delivery. Effects of these two genes on thrombosis in local anastomotic vessels, the expressions of proliferating cell nuclear antigen(PCNA) and PDGF-B mRNA by VSMCs and the proliferation of vascular intima were observed with the methods of routine pathological, immuno-histochemical staining, in situ hybridization and morphometry. RESULTS: PDGF-B antisense oligonucleotide and tissue-type plasminogen activator gene were succesfully transfected. These two genes significantly inhibited the expressions of PCNA and PDGF-B mRNA in intimal VSMCs with the inhibitory rates of 65.01% and 81.75%, respectively. The local intimal thickness and area also reduce markablely and the thrombosis of the anastomosis was prevented followed by the reduction of the anastomotic restenotic rate of 62.63%. CONCLUSION: Co-transfection of PDGF-B antisense oligonucleotide and tissue-type plasminogen activator gene inhibits the dog experimental anastomotic restenosis after coronary bypass.
